Global Recombinant Human Thrombin for Surgical Hemostasis 麻豆原创 Growth 2024-2030

Publication ID:

LPI07241750

Publication Date:

July 8, 2024

Pages:

118

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Recombinant Human Thrombin for Surgical Hemostasis is a medication or product that contains artificially produced human thrombin, which is used in surgical procedures to promote blood clotting and control bleeding. Thrombin is a protein involved in the blood clotting process, and when applied topically or locally during surgery, it helps to accelerate the formation of blood clots and stop bleeding. This product is commonly used in various surgical specialties, such as cardiovascular surgery, orthopedic surgery, and general surgery, to help achieve hemostasis and prevent excessive bleeding.
The global Recombinant Human Thrombin for Surgical Hemostasis market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淩ecombinant Human Thrombin for Surgical Hemostasis Industry Forecast鈥� looks at past sales and reviews total world Recombinant Human Thrombin for Surgical Hemostasis sales in 2023, providing a comprehensive analysis by region and market sector of projected Recombinant Human Thrombin for Surgical Hemostasis sales for 2024 through 2030. With Recombinant Human Thrombin for Surgical Hemostasis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Human Thrombin for Surgical Hemostasis industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Human Thrombin for Surgical Hemostasis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Human Thrombin for Surgical Hemostasis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Recombinant Human Thrombin for Surgical Hemostasis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human Thrombin for Surgical Hemostasis and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human Thrombin for Surgical Hemostasis.
United States market for Recombinant Human Thrombin for Surgical Hemostasis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Recombinant Human Thrombin for Surgical Hemostasis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Recombinant Human Thrombin for Surgical Hemostasis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Recombinant Human Thrombin for Surgical Hemostasis players cover Takeda, Bayer, CSL, Grifols, GE Healthcare, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human Thrombin for Surgical Hemostasis market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Based Bovine
Based Human
Others
Segmentation by Application:
Hospitals
Diagnostics & Clinics
Academic and Research Institute
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Takeda
Bayer
CSL
Grifols
GE Healthcare
Hualan Biological
Haematologic Technologies
Pfizer
Octapharma
Omrix Biopharmaceuticals
Shanghai RAAS
Key Questions Addressed in this Report
What is the 10-year outlook for the global Recombinant Human Thrombin for Surgical Hemostasis market?
What factors are driving Recombinant Human Thrombin for Surgical Hemostasis market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Human Thrombin for Surgical Hemostasis market opportunities vary by end market size?
How does Recombinant Human Thrombin for Surgical Hemostasis break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Recombinant Human Thrombin for Surgical Hemostasis Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Recombinant Human Thrombin for Surgical Hemostasis by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Recombinant Human Thrombin for Surgical Hemostasis by Country/Region, 2019, 2023 & 2030
2.2 Recombinant Human Thrombin for Surgical Hemostasis Segment by Type
2.2.1 Based Bovine
2.2.2 Based Human
2.2.3 Others
2.3 Recombinant Human Thrombin for Surgical Hemostasis Sales by Type
2.3.1 Global Recombinant Human Thrombin for Surgical Hemostasis Sales 麻豆原创 Share by Type (2019-2024)
2.3.2 Global Recombinant Human Thrombin for Surgical Hemostasis Revenue and 麻豆原创 Share by Type (2019-2024)
2.3.3 Global Recombinant Human Thrombin for Surgical Hemostasis Sale Price by Type (2019-2024)
2.4 Recombinant Human Thrombin for Surgical Hemostasis Segment by Application
2.4.1 Hospitals
2.4.2 Diagnostics & Clinics
2.4.3 Academic and Research Institute
2.5 Recombinant Human Thrombin for Surgical Hemostasis Sales by Application
2.5.1 Global Recombinant Human Thrombin for Surgical Hemostasis Sale 麻豆原创 Share by Application (2019-2024)
2.5.2 Global Recombinant Human Thrombin for Surgical Hemostasis Revenue and 麻豆原创 Share by Application (2019-2024)
2.5.3 Global Recombinant Human Thrombin for Surgical Hemostasis Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Recombinant Human Thrombin for Surgical Hemostasis Breakdown Data by Company
3.1.1 Global Recombinant Human Thrombin for Surgical Hemostasis Annual Sales by Company (2019-2024)
3.1.2 Global Recombinant Human Thrombin for Surgical Hemostasis Sales 麻豆原创 Share by Company (2019-2024)
3.2 Global Recombinant Human Thrombin for Surgical Hemostasis Annual Revenue by Company (2019-2024)
3.2.1 Global Recombinant Human Thrombin for Surgical Hemostasis Revenue by Company (2019-2024)
3.2.2 Global Recombinant Human Thrombin for Surgical Hemostasis Revenue 麻豆原创 Share by Company (2019-2024)
3.3 Global Recombinant Human Thrombin for Surgical Hemostasis Sale Price by Company
3.4 Key Manufacturers Recombinant Human Thrombin for Surgical Hemostasis Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Human Thrombin for Surgical Hemostasis Product Location Distribution
3.4.2 Players Recombinant Human Thrombin for Surgical Hemostasis Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for Recombinant Human Thrombin for Surgical Hemostasis by Geographic Region
4.1 World Historic Recombinant Human Thrombin for Surgical Hemostasis 麻豆原创 Size by Geographic Region (2019-2024)
4.1.1 Global Recombinant Human Thrombin for Surgical Hemostasis Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Recombinant Human Thrombin for Surgical Hemostasis Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Recombinant Human Thrombin for Surgical Hemostasis 麻豆原创 Size by Country/Region (2019-2024)
4.2.1 Global Recombinant Human Thrombin for Surgical Hemostasis Annual Sales by Country/Region (2019-2024)
4.2.2 Global Recombinant Human Thrombin for Surgical Hemostasis Annual Revenue by Country/Region (2019-2024)
4.3 Americas Recombinant Human Thrombin for Surgical Hemostasis Sales Growth
4.4 APAC Recombinant Human Thrombin for Surgical Hemostasis Sales Growth
4.5 Europe Recombinant Human Thrombin for Surgical Hemostasis Sales Growth
4.6 Middle East & Africa Recombinant Human Thrombin for Surgical Hemostasis Sales Growth
5 Americas
5.1 Americas Recombinant Human Thrombin for Surgical Hemostasis Sales by Country
5.1.1 Americas Recombinant Human Thrombin for Surgical Hemostasis Sales by Country (2019-2024)
5.1.2 Americas Recombinant Human Thrombin for Surgical Hemostasis Revenue by Country (2019-2024)
5.2 Americas Recombinant Human Thrombin for Surgical Hemostasis Sales by Type (2019-2024)
5.3 Americas Recombinant Human Thrombin for Surgical Hemostasis Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Human Thrombin for Surgical Hemostasis Sales by Region
6.1.1 APAC Recombinant Human Thrombin for Surgical Hemostasis Sales by Region (2019-2024)
6.1.2 APAC Recombinant Human Thrombin for Surgical Hemostasis Revenue by Region (2019-2024)
6.2 APAC Recombinant Human Thrombin for Surgical Hemostasis Sales by Type (2019-2024)
6.3 APAC Recombinant Human Thrombin for Surgical Hemostasis Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Recombinant Human Thrombin for Surgical Hemostasis by Country
7.1.1 Europe Recombinant Human Thrombin for Surgical Hemostasis Sales by Country (2019-2024)
7.1.2 Europe Recombinant Human Thrombin for Surgical Hemostasis Revenue by Country (2019-2024)
7.2 Europe Recombinant Human Thrombin for Surgical Hemostasis Sales by Type (2019-2024)
7.3 Europe Recombinant Human Thrombin for Surgical Hemostasis Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Recombinant Human Thrombin for Surgical Hemostasis by Country
8.1.1 Middle East & Africa Recombinant Human Thrombin for Surgical Hemostasis Sales by Country (2019-2024)
8.1.2 Middle East & Africa Recombinant Human Thrombin for Surgical Hemostasis Revenue by Country (2019-2024)
8.2 Middle East & Africa Recombinant Human Thrombin for Surgical Hemostasis Sales by Type (2019-2024)
8.3 Middle East & Africa Recombinant Human Thrombin for Surgical Hemostasis Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Human Thrombin for Surgical Hemostasis
10.3 Manufacturing Process Analysis of Recombinant Human Thrombin for Surgical Hemostasis
10.4 Industry Chain Structure of Recombinant Human Thrombin for Surgical Hemostasis
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Human Thrombin for Surgical Hemostasis Distributors
11.3 Recombinant Human Thrombin for Surgical Hemostasis Customer
12 World Forecast Review for Recombinant Human Thrombin for Surgical Hemostasis by Geographic Region
12.1 Global Recombinant Human Thrombin for Surgical Hemostasis 麻豆原创 Size Forecast by Region
12.1.1 Global Recombinant Human Thrombin for Surgical Hemostasis Forecast by Region (2025-2030)
12.1.2 Global Recombinant Human Thrombin for Surgical Hemostasis Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Recombinant Human Thrombin for Surgical Hemostasis Forecast by Type (2025-2030)
12.7 Global Recombinant Human Thrombin for Surgical Hemostasis Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Takeda
13.1.1 Takeda Company Information
13.1.2 Takeda Recombinant Human Thrombin for Surgical Hemostasis Product Portfolios and Specifications
13.1.3 Takeda Recombinant Human Thrombin for Surgical Hemostasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Takeda Main Business Overview
13.1.5 Takeda Latest Developments
13.2 Bayer
13.2.1 Bayer Company Information
13.2.2 Bayer Recombinant Human Thrombin for Surgical Hemostasis Product Portfolios and Specifications
13.2.3 Bayer Recombinant Human Thrombin for Surgical Hemostasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Bayer Main Business Overview
13.2.5 Bayer Latest Developments
13.3 CSL
13.3.1 CSL Company Information
13.3.2 CSL Recombinant Human Thrombin for Surgical Hemostasis Product Portfolios and Specifications
13.3.3 CSL Recombinant Human Thrombin for Surgical Hemostasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 CSL Main Business Overview
13.3.5 CSL Latest Developments
13.4 Grifols
13.4.1 Grifols Company Information
13.4.2 Grifols Recombinant Human Thrombin for Surgical Hemostasis Product Portfolios and Specifications
13.4.3 Grifols Recombinant Human Thrombin for Surgical Hemostasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Grifols Main Business Overview
13.4.5 Grifols Latest Developments
13.5 GE Healthcare
13.5.1 GE Healthcare Company Information
13.5.2 GE Healthcare Recombinant Human Thrombin for Surgical Hemostasis Product Portfolios and Specifications
13.5.3 GE Healthcare Recombinant Human Thrombin for Surgical Hemostasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 GE Healthcare Main Business Overview
13.5.5 GE Healthcare Latest Developments
13.6 Hualan Biological
13.6.1 Hualan Biological Company Information
13.6.2 Hualan Biological Recombinant Human Thrombin for Surgical Hemostasis Product Portfolios and Specifications
13.6.3 Hualan Biological Recombinant Human Thrombin for Surgical Hemostasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Hualan Biological Main Business Overview
13.6.5 Hualan Biological Latest Developments
13.7 Haematologic Technologies
13.7.1 Haematologic Technologies Company Information
13.7.2 Haematologic Technologies Recombinant Human Thrombin for Surgical Hemostasis Product Portfolios and Specifications
13.7.3 Haematologic Technologies Recombinant Human Thrombin for Surgical Hemostasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Haematologic Technologies Main Business Overview
13.7.5 Haematologic Technologies Latest Developments
13.8 Pfizer
13.8.1 Pfizer Company Information
13.8.2 Pfizer Recombinant Human Thrombin for Surgical Hemostasis Product Portfolios and Specifications
13.8.3 Pfizer Recombinant Human Thrombin for Surgical Hemostasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Pfizer Main Business Overview
13.8.5 Pfizer Latest Developments
13.9 Octapharma
13.9.1 Octapharma Company Information
13.9.2 Octapharma Recombinant Human Thrombin for Surgical Hemostasis Product Portfolios and Specifications
13.9.3 Octapharma Recombinant Human Thrombin for Surgical Hemostasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Octapharma Main Business Overview
13.9.5 Octapharma Latest Developments
13.10 Omrix Biopharmaceuticals
13.10.1 Omrix Biopharmaceuticals Company Information
13.10.2 Omrix Biopharmaceuticals Recombinant Human Thrombin for Surgical Hemostasis Product Portfolios and Specifications
13.10.3 Omrix Biopharmaceuticals Recombinant Human Thrombin for Surgical Hemostasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Omrix Biopharmaceuticals Main Business Overview
13.10.5 Omrix Biopharmaceuticals Latest Developments
13.11 Shanghai RAAS
13.11.1 Shanghai RAAS Company Information
13.11.2 Shanghai RAAS Recombinant Human Thrombin for Surgical Hemostasis Product Portfolios and Specifications
13.11.3 Shanghai RAAS Recombinant Human Thrombin for Surgical Hemostasis Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Shanghai RAAS Main Business Overview
13.11.5 Shanghai RAAS Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.